{'52WeekChange': 0.41999996,
 'SandP52WeekChange': 0.0644362,
 'address1': '35 CambridgePark Drive',
 'address2': '4th Floor',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 12.98,
 'askSize': 900,
 'averageDailyVolume10Day': 211475,
 'averageVolume': 359688,
 'averageVolume10days': 211475,
 'beta': 1.618471,
 'beta3Year': None,
 'bid': 10.6,
 'bidSize': 800,
 'bookValue': 1.675,
 'category': None,
 'circulatingSupply': None,
 'city': 'Cambridge',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 10.96,
 'dayLow': 10.46,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -5.463,
 'enterpriseToRevenue': 105.108,
 'enterpriseValue': 410658240,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 10.707429,
 'fiftyTwoWeekHigh': 12.75,
 'fiftyTwoWeekLow': 4.26,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 38248380,
 'forwardEps': -1.64,
 'forwardPE': -6.493902,
 'fromCurrency': None,
 'fullTimeEmployees': 83,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.09054,
 'heldPercentInstitutions': 0.86765,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/syros.com',
 'longBusinessSummary': 'Syros Pharmaceuticals, Inc., a biopharmaceutical '
                        'company, focuses on the development of treatments for '
                        'cancer and monogenic diseases, and building a '
                        "pipeline of gene control medicines. The company's "
                        'lead product candidates are SY-1425, a selective '
                        'retinoic acid receptor alpha agonist, which is in a '
                        'Phase II clinical trial for genomically defined '
                        'subset of patients with acute myeloid leukemia and '
                        'myelodysplastic syndrome; and SY-5609, a '
                        'cyclin-dependent kinase 7 inhibitor, which is in a '
                        'Phase I clinical trial in patients with select '
                        'advanced solid tumors. It has target discovery, '
                        'research collaboration, and option agreement with '
                        'Incyte Corporation to identify therapeutic targets '
                        'with a focus on myeloproliferative neoplasms; and a '
                        'license agreement with TMRC Co. Ltd. for the '
                        'development and commercialization of tamibarotene. '
                        'The company was formerly known as LS22, Inc. and '
                        'changed its name to Syros Pharmaceuticals, Inc. in '
                        'August 2012. Syros Pharmaceuticals, Inc. was founded '
                        'in 2011 and is headquartered in Cambridge, '
                        'Massachusetts.',
 'longName': 'Syros Pharmaceuticals, Inc.',
 'market': 'us_market',
 'marketCap': 486632576,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_236291486',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -76203000,
 'nextFiscalYearEnd': 1640908800,
 'open': 10.86,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '617 744 1340',
 'previousClose': 11.02,
 'priceHint': 2,
 'priceToBook': 6.358209,
 'priceToSalesTrailing12Months': 124.55402,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 10.96,
 'regularMarketDayLow': 10.46,
 'regularMarketOpen': 10.86,
 'regularMarketPreviousClose': 11.02,
 'regularMarketPrice': 10.86,
 'regularMarketVolume': 223291,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 45693200,
 'sharesPercentSharesOut': 0.0698,
 'sharesShort': 3190583,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 2851334,
 'shortName': 'Syros Pharmaceuticals, Inc.',
 'shortPercentOfFloat': 0.1294,
 'shortRatio': 7.75,
 'startDate': None,
 'state': 'MA',
 'strikePrice': None,
 'symbol': 'SYRS',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -1.782,
 'twoHundredDayAverage': 8.363453,
 'volume': 223291,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.syros.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '02140'}